American Oncology Network Announces Voluntary Delisting From Nasdaq
21 Maggio 2024 - 12:00PM
American Oncology Network (“AON” or the “Company”) (Nasdaq: AONC),
a rapidly growing network of community-based oncology practices,
announced today its decision to voluntarily delist its Class A
common stock and warrants from The Nasdaq Capital Market
("Nasdaq"). The Company’s decision to delist its securities from
Nasdaq was recommended to the Board of Directors (the "Board") of
the Company by a Special Committee (the "Special Committee") of the
Board comprised solely of independent directors.
The Company intends to file a Form 25 with the Securities and
Exchange Commission (the “SEC”) to delist its Class A common stock
and warrants from Nasdaq and to deregister its Class A common stock
and warrants under Section 12(b) of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), on or about May 31, 2024,
and as a result, the Company expects that the last trading day of
its Class A common stock and warrants on Nasdaq will be on or about
June 7, 2024.
In making its determination, the Special Committee concluded
that delisting the Company’s securities from Nasdaq is in the best
interests of the Company and its stakeholders. The Special
Committee’s recommendation and the Board’s decision were the
product of careful review and consideration of a number of factors,
including, but not limited to, (1) the lack of research coverage of
the Company by securities and industry analysts, (2) the lack of an
active trading market for its securities on Nasdaq, and (3) the
required personnel resources and expenses relating to continued
Exchange Act and Nasdaq disclosure and reporting requirements and
related regulatory burdens, which have resulted and would continue
to result in significant operating expense and attention of the
Company’s management team.
Todd Schonherz, Chief Executive Officer, commented, “AON has
delivered an impressive five-year revenue CAGR of 42% and continues
to experience strong momentum with the addition of 40 providers and
four new practices to the network year-to-date. AON is in a healthy
financial position with a robust balance sheet of over $100 million
in cash and short-term securities as of March 31, 2024. While going
public allowed us to raise growth capital and provide equity to key
stakeholders, we believe that we will be better positioned to
maximize shareholder value going forward by delisting.”
Following the delisting of the Company’s common stock and
warrants from Nasdaq, the Company expects that its common stock and
warrants will be quoted for trading on a market operated by OTC
Markets Group Inc. (the “OTC”) so that a trading market may
continue to exist for such securities. There is no guarantee,
however, that a broker will continue to make a market in the common
stock and warrants.
About American Oncology Network
American Oncology Network (AON) (Nasdaq: AONC) is an alliance of
physicians and seasoned healthcare leaders partnering to ensure the
long-term success and viability of community oncology and other
specialties. Founded in 2018, AON’s rapidly expanding network
represents more than 240 providers practicing across 21 states. AON
pioneers innovative healthcare solutions through its physician-led
model, fostering value-based care that improves patient outcomes
while reducing costs and expanding access to quality care. AON
equips its network physicians with the tools they need to thrive
independently while providing comprehensive support, integrated
revenue-diversifying ancillary services, and practice management
expertise, enabling physicians to focus on what matters most –
providing the highest standard of care for every patient. AON is
committed to promoting health equity by addressing disparities in
cancer care and ensuring that all patients have access to the care
they need to achieve optimal health outcomes. With a focus on
innovation and collaboration, AON is shaping the future of
community oncology. Learn more at www.AONcology.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's strategy, intentions to
voluntarily delist its securities from Nasdaq and any anticipated
results of such actions. Forward-looking statements are typically
identified by words such as “plan,” “believe,” “expect,”
“anticipate,” “intend,” “continue,” “could,” “may,” “might,”
“possible,” “potential,” “predict,” “should,” “would” and other
similar words and expressions, but the absence of these words does
not mean that a statement is not forward-looking. These statements
are based on current expectations as of the date of this press
release and involve a number of risks and uncertainties, which may
cause results to differ materially from those indicated by these
forward-looking statements. Many important factors could cause
actual future events to differ materially from the forward-looking
statements in this press release, including, but not limited to,
future liquidity of the Company's securities, the Company’s
continued growth, changes in the Company's board of directors and
executive management, and the Company's dependence on its executive
management team. The foregoing list of factors is not
exhaustive.
You should carefully consider the foregoing factors and the
other risks and uncertainties described under the caption "Risk
Factors" in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2023, filed with the SEC on March 28, 2024,
as amended on April 29, 2024, and the Company's other filings with
the SEC. These SEC filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and we assume no obligation and do not
intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise. We do not give any assurance that we will achieve our
expectations.
Investor Contact:Solebury Strategic
CommunicationsInvestors@AONcology.com
Grafico Azioni American Oncology Network (NASDAQ:AONC)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni American Oncology Network (NASDAQ:AONC)
Storico
Da Mar 2024 a Mar 2025